Key Takeaways
- JPMorgan elevated UNH’s price target from $420 to $466 while maintaining its “overweight” stance
- Mizuho increased its price objective to $460 from $440, reaffirming an “outperform” designation
- The stock reached a fresh 52-week peak near $413 on June 9, climbing over 20% year-to-date in 2026
- First quarter 2026 results exceeded projections with $111.7B revenue and $7.23 earnings per share
- The medical care ratio enhanced to 83.9% from 84.8%, indicating stronger profit margins
UnitedHealth Group (UNH) finished trading at $407.73 on June 10, declining 1.28% during the session, though remaining close to its 52-week peak following multiple positive analyst revisions earlier that week.
UnitedHealth Group Incorporated, UNH
On June 8, JPMorgan elevated its price objective for UNH from $420 to $466, sustaining an “overweight” designation. This represents the most aggressive Street forecast, positioned approximately 14% beyond the stock’s trading level at that moment.
Almost simultaneously, Mizuho announced its own upward revision — boosting its target from $440 to $460 while preserving an “outperform” recommendation.
Mizuho informed investors that the managed care industry is entering a more stable regulatory environment. Unexpected policy shifts from Washington have diminished after three turbulent years, creating a more favorable operating climate.
Shares touched a new 52-week pinnacle around $413 on June 9, gaining more than 20% during 2026 thus far.
The Turbulent 2025 Backdrop
Grasping the current analyst enthusiasm requires examining last year’s challenges.
In May 2025, CEO Andrew Witty departed unexpectedly. The board reappointed previous leader Stephen Hemsley. The organization withdrew its 2025 guidance as healthcare expenses exceeded projections.
Additionally, the Justice Department initiated an examination of UnitedHealth’s Medicare reimbursement methods. This investigation continues.
Investors reacted by selling aggressively. UNH declined to approximately $300–$312 per share — substantially below its record closing peak of $603.20 from November 2024. Berkshire Hathaway acquired shares around $271 during the selloff, subsequently liquidating the complete stake in Q1 2026.
The 2026 Transformation
First quarter 2026 performance drove the recovery. UnitedHealth delivered $111.7 billion in revenue alongside adjusted earnings of $7.23 per share, surpassing analyst expectations. Shares surged over 8% following the announcement.
The metric that truly resonated with investors was the medical care ratio — representing the portion of premium income allocated to claims payments. This figure improved to 83.9% from 84.8% twelve months prior. A declining ratio means the company retains greater premium revenue as earnings. This enhancement restored institutional confidence more effectively than any executive statements.
Zacks consensus projections for Q2 anticipate $4.84 EPS alongside $110.05 billion in revenue. Annual estimates forecast $18.32 EPS with $443.7 billion in revenue, suggesting approximately 12% earnings expansion year-over-year.
UNH presently commands a forward P/E multiple of 22.55, exceeding the sector average of 19.11.
JPMorgan’s optimistic thesis depends on three favorable outcomes: the DOJ Medicare inquiry concluding without substantial financial sanctions, healthcare costs maintaining their downward trajectory, and leadership executing on its 13%–16% long-term expansion objective.
Berkshire’s departure — liquidating a position purchased near the bottom, rapidly — represents one signal certain market participants are monitoring.
The Medical-HMOs sector currently maintains a Zacks Industry Rank of 25, positioning it within the top 11% of all monitored sectors.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
